^
    Back
    Association details:
    Biomarker:MGMT promoter methylation
    Cancer:Ewing Sarcoma
    Drug:temozolomide (DNA synthesis inhibitor) +
    irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan

    Excerpt:
    ...Amplification the methylation-specific Polymerase Chain Reaction products will be electrophoresed on a 2% agarose gel and will visualized with UV light`Assessment of MGMT promoter methylation...
    Trial ID:
    MGMTLiberati
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    The MGMT (O6-methylguanine–DNA methyltransferase) promotes methylation and clinical outcomes of salvage temozolomide and irinotecan chemotherapy in progressive Ewing sarcoma: A preliminary report

    Published date:
    05/19/2021
    Excerpt:
    ...to assess the influence of MGMT promoter methylation status on response rate, time to progression (TTP), and overall survival (OS) following salvage irinotecan and temozolomide (IT) chemotherapy....The corresponding median OS was 69.4 and 14.3 months in favor of the methylated group; p=0.3....This preliminary data suggests a possible prognostic role for MGMT promoter methylation, with a markedly extended median OS for the methylated group.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e23507